BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27
19th November, 2026

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051

SYMBOL: BETA

Re:- Press Release Pursuant to Regulation 30 of Listing Regulations- Beta Drugs Limited ("Beta") forms Oncology Joint Venture with IMGSA Groupe SPA ("IMGSA")

Dear Madam/Sir

We are pleased to inform you that the **Beta Drugs Limited ("Beta") forms Oncology Joint Venture with IMGSA Groupe SPA ("IMGSA") in Algeria.**

Please find enclosed a copy of the press release being issued in this regard.

Kindly take the above information on record.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Beta Drugs Limited
Company Secretary
ACS - 24684

Rajni Brar
Company Secretary

Beta Drugs Limited (“Beta”) forms Oncology Joint Venture with IMGSA Groupe SPA (“IMGSA”)

JV to acquire IMGSA’s oncology formulation plant for US$8.7 million; Beta to hold 49% and manage the operations of the JV



Panchkula, Nov 19th, 2026 – Beta Drugs Limited (“Beta” or “the Company”) today announced that it has entered into a **joint venture (“JV”)** with IMGSA Groupe SPA (“IMGSA”), a prominent and leading pharmaceutical and medical devices company in Algeria. Beta will hold a **49% stake** in the JV, with the remaining 51% held by IMGSA (the “Transaction”). The JV will acquire IMGSA’s **oncology formulation plant** for a total consideration of US$8.7 million. The plant is among **few plants in Algeria** for manufacturing of oncology formulations and has been qualified by Algerian regulatory authority for supply in Algeria tenders. Algeria oncology market is primarily a **tender market** and there has been a consistent impetus provided by the government of Algeria for **localisation of pharmaceutical manufacturing**.

From a long-standing partnership to an equity partnership

IMGSA is one of Algeria’s leading healthcare companies, with an established presence across antibiotics, insulins and medical devices. The group has a diversified industrial presence in Algeria through its operations in the field of agriculture, chemicals and other industrial sectors including healthcare and pharmaceuticals. Beta has had a long-standing relationship with IMGSA over the last 4 years, during which Beta has supplied semi-finished and finished formulations to IMGSA and assisted IMGSA in product registrations for Algeria market. The product registrations would be transferred to the JV as part of the Transaction.

The JV is intended to deepen the partnership between Beta and IMGSA. By moving from a supplier to an Equity investor, the two companies expect to broaden the relationship and align

their long-term interests in building a strong oncology business in Algeria and North African markets. IMGSA is a leading exporter of pharmaceuticals to Tunisia, Mauritania and other North African markets and the JV will leverage the distribution network of IMGSA to cater to these markets.

Transaction structure

- The JV will acquire the oncology plant from IMGSA for a total consideration of US$8.7 million.
- Part of the consideration to be settled by issue equity shares to IMGSA.
- Beta will infuse US$ 3 Million in the JV over a period of 3 years.
- Beta will transfer formulation technology to the JV as part of the Transaction

  .

Acquisition of Oncology formulation plant

As part of the Transaction, the plant being acquired by the JV has manufacturing capabilities in both injectable and oral solid dosage forms, giving the JV a broad platform to produce a range of oncology products locally in Algeria. The plant is among a few oncology dedicated plants in Algeria and has been qualified by Algeria FDA for supply for national tender. The JV will file dossiers for products registrations from the plant with support from our partner to enable accelerated launch of our products in Algeria and other North African markets

Positioned for a fast-growing market

The Algerian oncology market is valued at approximately US$1 billion and growing at a fast clip. Oncology is a tender driven market in Algeria and the government of Algeria has been incentivising local manufacturing of critical life-saving pharmaceutical products. The JV, with the acquisition of oncology formulation plant, is well positioned to capture significant market share in the national tender by combining Beta's research, development, manufacturing and supply chain capabilities with the marketing and distribution infrastructure of IMGSA.

Governance and management

Under the terms of the agreement, the JV's Board will comprise five directors, three appointed by Beta and two by IMGSA. The CEO/ MD of the JV will be appointed by Beta and will be responsible for the day-to-day operations of the JV.

Management commentary

Rahul Batra, MD, Beta Drugs Limited, said: *"Our relationship with IMGSA has grown steadily over many years, and this joint venture marks a natural next step for us to deepen our relationship and commitment to the Algerian market. By bringing our manufacturing technology and know-how to a well-equipped and qualified oncology plant and pairing it with IMGSA's strong market presence in Algeria, we aim to improve access to quality cancer therapies for patients in Algeria."*

Mr. Toufik Haouam, MD, IMGSA Groupe SPA, said: *"Beta has been a trusted partner for many years. This equity partnership strengthens our oncology capabilities and supports our commitment to local manufacturing to meet the growing needs of Algerian patients. We believe this is JV is well positioned to serve the customers and patients in Algeria with high-quality*

oncology formulations and reinforces our commitment to localisation of manufacturing of critical pharmaceutical products in Algeria"

The Transaction is subject to customary conditions and regulatory approvals, as applicable.

About Beta Drugs Limited

Beta is a leading integrated oncology company with presence across branded formulations, CMO, exports and oncology APIs. Beta is among the largest suppliers of oncology formulations in India with a track record of supplying lifesaving critical oncology formulations to hospitals, marquee pharmaceutical companies and exporting them to regulated and semi-regulated markets

About IMGSA Groupe SPA

IMGSA is a prominent and leading pharmaceutical and medical devices company in Algeria, with a presence across antibiotics, insulins and medical devices. Established in 2003, IMGSA has expanded rapidly in the field sectors of healthcare, real estate, agriculture and chemicals. IMGSA holds various product registrations in oncology and has been a supplier in tenders for Algeria market

Forward-looking statements

This press release may contain forward-looking statements that are based on current expectations and assumptions and are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied. Beta undertakes no obligation to update any forward-looking statements, except as required by law.